Country: Malta
Language: English
Source: Medicines Authority
MESALAZINE
Sofar S.p.A Via Isonzo 8, 20135 - Milano, Italy
A07EC02
MESALAZINE 400 mg
GASTRO-RESISTANT TABLET
MESALAZINE 400 mg
POM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
Withdrawn
2005-10-14
_PATIENT INFORMATION LEAFLET _ 1 PENTACOL ® 400 GASTRO-RESISTANT, MODIFIED-RELEASE TABLETS ATC AO7EC02 MESALAZINE COMPOSITION Each 400 mg tablet contains: _ACTIVE INGREDIENT_ _: _ Mesalazine (5-aminosalicylic acid) 400 mg. _EXCIPIENTS_ _:_ Microcrystalline cellulose; Sodium carboxymethyl starch; Maize starch; Magnesium stearate; Polyvinylpyrrolidone; Mannitol; Silicon dioxide; Methacrylic acid copolymers; Talc; Titanium dioxide; Red ferric oxide; Triethyl citrate. PHARMACEUTICAL DOSAGE FORM AND PRESENTATION Box of 60 gastroresistant modified-release tablets containing 400 mg, oral use. PHARMACOLOGIC AND THERAPEUTIC CATEGORY Intestinal anti-inflammatory agents - mesalazine. MARKETING AUTHORIZATION HOLDER SOFAR S.p.A., Via Firenze 40, Trezzano Rosa MI (Italy) MANUFACTURER AND CONTROL SITE SOFAR S.p.A., Via Firenze 40, Trezzano Rosa MI (Italy) WHEN TO USE THIS MEDICINAL PRODUCT THERAPEUTIC INDICATIONS Ulcerative colitis, Crohn’s disease, acute and chronic intestinal idiopathic inflammation, localized in the distal ileum and in the colon. INFORMATION FOR THE CORRECT USE OF THIS MEDICINAL PRODUCT CONTRA-INDICATIONS Hypersensitivity to mesalazine, to salicylates in general or to any one of the excipients. Active peptic ulcer. Severe nephropathy. Avoid use during the last weeks of pregnancy. Avoid use in children under six years of age. PRECAUTIONS Particular caution should be taken in patients with kidney or liver injury and in patients under treatment with oral hypoglycemics, diuretics, coumarins and corticosteroids. Prolonged use may lead to sensitization. Use should be avoided in patients with kidney failure. INTERACTIONS During treatment with PENTACOL tablets, avoid use of lactulose Read the complete document
Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Pentacol 400 mg, gastro-resistant modified-release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 400 mg tablet contains: _ACTIVE INGREDIENT_ _: _ Mesalazine (5-aminosalicylic acid) 400 mg. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant tablets 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ulcerative colitis, Crohn’s disease, acute and chronic intestinal idiopathic inflammation, localized in the distal ileum and in the colon. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The average adult dose is 2 tablets three times daily. In acute disease the maximum dose is up to 10 tablets per day, according to the physician’s directions. PENTACOL tablets must be swallowed whole (do not break or chew the tablets) with a glass of water, away from meals. For patients taking this medicine for the first time, it is advisable to begin treatment at a lower dose and increase it gradually over a few days until the full daily dosage is reached. Avoid use in children under six years of age. Treatment in the active phase is 4-6 weeks. For long-term treatments to maintain remission, the daily dosage of PENTACOL gastro-resistant, modified-release tablets must be established by the physician depending on the patient state and the disease evolution. 4.3 CONTRAINDICATIONS Hypersensitivity to mesalazine, to salicylates in general or to any one of the excipients. Active peptic ulcer. Severe nephropathy. Avoi Read the complete document